Interesting data on the tafamidis-statin interaction--> related to BCRP substrates Presented at #ACC26 #MedIQACC26

#ACC26 Prem Soman presented in an LBCT session the updated outcomes from ATTRibute-CM OLE - patients on continuous acoramidis vs placebo to acoramidis out to 54 months.
The evolution of ATTR-CM treatment is a good story to tell
#MedIQACC26

#ACC26 Lots of progress in ATTR-CM, but there remains a large unmet need based on this survey
#MedIQACC26

#ACC26 consistent benefit from vutrisiran regardless of diastolic parameters at baseline. A post-hoc analysis from HELIOS-B
#MedIQACC26

#ACC26 Lots of good insights from MaesTTRo - an ongoing prospective ATTR registry
#MedIQACC26

#ACC26 Great data from @maz_hanna et al
Rate of conversion from PYP/HDP negative to positive - typically over 3 years, and CTS/SS identifies the high risk group. This supports our current practice of repeat evaluation once every 2 years in CTS+
#MedIQACC26

#ACC26 A super rare case from our group - Misfolded on the Right - delayed diagnosis due to assumptions of worsening status usually related to underlying disease
#MedIQACC26

#ACC26 low serum TTR had worse KCCQ, and improvement in TTR on acoramidis led to improved KCCQ
#MedIQACC26

#ACC26 vutrisiran reduces the progression of ATTR-CM
#MedIQACC26

#ACC26 longer term data from ATTRibute-CM/OLE on acoramidis effect on serum TTR and KCCQ-OS
#MedIQACC26

#ACC26 AGENT ATTR - screening for ATTR-CM using multi-agent AI
#MedIQACC26

#ACC26 Vutrisiran resulted in better effect on KCCQ components compared to placebo in HELIOS-B
#MedIQACC26

#ACC26 AF/AFL in transthyretin amyloidosis is common and is associated with worse outcomes
#MedIQACC26

#ACC26 - Cystatin C-GFR reclassifies NAC staging in 20% of patients with transnthyretin amyloidosis
#MedIQACC26

Thank you to Ahmad Masri, MD for his live updates on ATTR-CM from #ACC26 this past weekend! Check out this thread for highlights.
#MedIQACC26